MedTrace Logo

CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer

NCT02850536 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-10-21

No results posted yet for this study

Summary

This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or pancreas cancer.

Conditions

  • Liver Metastases

Interventions

BIOLOGICAL

anti-CEA CAR-T cells

Gene modified patient T cells

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • Sorrento Therapeutics, Inc.

    collaborator INDUSTRY

  • Roger Williams Medical Center

    lead OTHER

Principal Investigators

  • Steven C. Katz, MD · Roger Williams Medical Center

  • Richard Schulick, MD · University of Colorado, Denver

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2018-12-31
Completion
2021-09-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02850536 on ClinicalTrials.gov